Bruce Cozadd Biography and Net Worth

Co-Founder, Chairman & CEO of Jazz Pharmaceuticals

Bruce C. Cozadd brings extensive experience in research and development, manufacturing and sales and marketing. After being inspired by the culture at ALZA where he started his career, Mr. Cozadd wanted to start a company where top talent can do their best and work inclusively as a team. It was under these ideals that Mr. Cozadd co-founded Jazz Pharmaceuticals Inc. in 2003.

Mr. Cozadd co-founded Jazz Pharmaceuticals, Inc. in 2003 and has served as our Chairman and Chief Executive Officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd serves on the board of Biotechnology Innovation Organization (BIO), a biotechnology trade association, where he serves on its Health Section Governing Board. Mr. Cozadd also serves on the boards of two non-profit organizations, The Nueva School and SFJAZZ. He received a B.S. from Yale University with a double major in molecular biophysics and biochemistry and economics and an M.B.A. from the Stanford Graduate School of Business.

What is Bruce C. Cozadd's net worth?: The estimated net worth of Bruce C. Cozadd is at least $52.15 million as of November 1st, 2024. Mr. Cozadd owns 428,976 shares of Jazz Pharmaceuticals stock worth more than $52,154,902 as of December 3rd. This net worth evaluation does not reflect any other assets that Mr. Cozadd may own. Additionally, Mr. Cozadd receives a salary of $2,440,000.00 as Co-Founder, Chairman & CEO at Jazz Pharmaceuticals. Learn More about Bruce C. Cozadd's net worth.
How old is Bruce C. Cozadd?: Mr. Cozadd is currently 60 years old. There are 6 older executives and no younger executives at Jazz Pharmaceuticals. Learn More on Bruce C. Cozadd's age.
What is Bruce C. Cozadd's salary?: As the Co-Founder, Chairman & CEO of Jazz Pharmaceuticals plc, Mr. Cozadd earns $2,440,000.00 per year. Learn More on Bruce C. Cozadd's salary.
How do I contact Bruce C. Cozadd?: The corporate mailing address for Mr. Cozadd and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Bruce C. Cozadd's contact information.
Has Bruce C. Cozadd been buying or selling shares of Jazz Pharmaceuticals?: Over the course of the past ninety days, Bruce C. Cozadd has sold $110,840.00 of Jazz Pharmaceuticals stock. Most recently, Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a transaction totalling $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at $47,547,699.84. Learn More on Bruce C. Cozadd's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 7 times. They sold a total of 13,626 shares worth more than $1,567,507.92. The most recent insider tranaction occured on November, 8th when EVP Neena M Patil sold 3,700 shares worth more than $456,617.00. Insiders at Jazz Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 11/8/2024.

Bruce C. Cozadd Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/1/2024	Sell	1,000	$110.84	$110,840.00	428,976
2/1/2023	Sell	1,000	$155.79	$155,790.00	367,078
1/3/2023	Sell	3,000	$159.86	$479,580.00	368,078
12/1/2022	Sell	1,000	$157.00	$157,000.00	371,078
11/10/2022	Sell	2,000	$150.00	$300,000.00	372,028
10/3/2022	Sell	45,185	$134.93	$6,096,812.05	374,028
9/6/2022	Sell	7,703	$153.18	$1,179,945.54	353,311
8/1/2022	Sell	7,301	$154.31	$1,126,617.31	354,311
7/5/2022	Sell	8,775	$157.28	$1,380,132.00	351,912
6/1/2022	Sell	6,362	$146.87	$934,386.94	351,987
5/2/2022	Sell	7,260	$156.63	$1,137,133.80	348,502
4/4/2022	Sell	10,772	$158.33	$1,705,530.76	346,062
2/1/2022	Sell	6,372	$139.23	$887,173.56
12/1/2021	Sell	6,748	$122.66	$827,709.68
11/1/2021	Sell	6,556	$134.75	$883,421.00
10/4/2021	Sell	6,598	$129.87	$856,882.26
8/2/2021	Sell	1,750	$169.98	$297,465.00	307,388
7/1/2021	Sell	10,850	$180.67	$1,960,269.50	308,888
5/5/2021	Sell	500	$170.00	$85,000.00	321,841
5/3/2021	Sell	1,500	$164.24	$246,360.00	321,841
4/1/2021	Sell	1,500	$164.96	$247,440.00	323,341
2/3/2021	Sell	1,500	$156.79	$235,185.00
1/4/2021	Sell	7,950	$162.01	$1,287,979.50	319,532
12/3/2020	Sell	250	$150.00	$37,500.00
12/1/2020	Sell	1,000	$140.58	$140,580.00
11/2/2020	Sell	1,000	$145.13	$145,130.00	331,180
10/1/2020	Sell	4,500	$141.94	$638,730.00	332,180
9/1/2020	Sell	500	$134.90	$67,450.00	336,680
8/27/2020	Sell	3,000	$130.00	$390,000.00
1/2/2020	Sell	1,250	$149.61	$187,012.50	300,138
12/2/2019	Sell	10,750	$150.00	$1,612,500.00
11/5/2019	Sell	500	$130.00	$65,000.00	311,855
10/1/2019	Sell	500	$130.00	$65,000.00
11/1/2018	Sell	1,300	$159.45	$207,285.00	278,615
10/1/2018	Sell	1,300	$167.99	$218,387.00	279,915
9/21/2018	Sell	1,300	$164.36	$213,668.00	281,215
8/1/2018	Sell	1,600	$173.90	$278,240.00	282,515
7/2/2018	Sell	1,600	$170.81	$273,296.00	284,115
6/1/2018	Sell	7,000	$168.86	$1,182,020.00
5/1/2018	Sell	1,000	$151.57	$151,570.00
4/2/2018	Sell	1,000	$150.01	$150,010.00	293,542
3/9/2018	Sell	1,000	$150.00	$150,000.00	294,542
2/28/2018	Sell	1,000	$150.00	$150,000.00	267,468
1/12/2018	Sell	3,000	$150.00	$450,000.00
10/2/2017	Sell	1,000	$150.00	$150,000.00
9/12/2017	Sell	1,000	$153.52	$153,520.00
5/11/2017	Sell	30,000	$153.47	$4,604,100.00	296,418
4/11/2017	Sell	1,000	$152.12	$152,120.00	308,491
8/9/2016	Sell	1,000	$150.00	$150,000.00
3/8/2016	Sell	2,500	$126.04	$315,100.00	302,566
2/9/2016	Sell	2,500	$111.37	$278,425.00	281,896
1/12/2016	Sell	2,500	$123.81	$309,525.00	284,396
12/8/2015	Sell	2,500	$139.72	$349,300.00	286,855
11/10/2015	Sell	2,500	$128.53	$321,325.00	289,355
10/13/2015	Sell	2,500	$131.50	$328,750.00	291,855
9/8/2015	Sell	2,500	$163.07	$407,675.00	294,355
7/14/2015	Sell	5,000	$177.79	$888,950.00
6/9/2015	Sell	5,000	$173.16	$865,800.00
4/14/2015	Sell	5,000	$181.45	$907,250.00
12/9/2014	Sell	5,000	$178.79	$893,950.00
9/9/2014	Sell	5,000	$170.32	$851,600.00
8/12/2014	Sell	5,000	$133.15	$665,750.00
7/8/2014	Sell	5,000	$155.00	$775,000.00
6/10/2014	Sell	5,000	$142.34	$711,700.00

Bruce C. Cozadd Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $122.72

$120.99

$123.02

50 Day Range

MA: $115.13

$107.32

$127.74

2 Week Range

Now: $122.72

$99.06

$134.17

Volume

136,575 shs

Average Volume

672,168 shs

Market Capitalization

$7.42 billion

P/E Ratio

17.28

Dividend Yield

N/A

Beta

0.57

Tim Sykes’ Urgent Trade Alert: “Make this move now”

From Timothy Sykes | Ad

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade

Bruce Cozadd Biography and Net Worth

What is Bruce C. Cozadd's net worth?

How old is Bruce C. Cozadd?

What is Bruce C. Cozadd's salary?

How do I contact Bruce C. Cozadd?

Has Bruce C. Cozadd been buying or selling shares of Jazz Pharmaceuticals?

Who are Jazz Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Jazz Pharmaceuticals?